ImageneBio (NASDAQ:IMA) Trading Up 2.9% – Should You Buy?

ImageneBio, Inc. (NASDAQ:IMA)’s stock price rose 2.9% during mid-day trading on Tuesday . The stock traded as high as $5.76 and last traded at $5.76. 3,596 shares traded hands during mid-day trading, a decline of 63% from the average daily volume of 9,627 shares. The stock had previously closed at $5.60.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on IMA shares. Wedbush reissued an “underperform” rating on shares of ImageneBio in a research report on Monday, May 11th. Wall Street Zen lowered ImageneBio from a “sell” rating to a “strong sell” rating in a report on Sunday, May 17th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of ImageneBio in a research report on Monday, June 29th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. According to MarketBeat.com, ImageneBio currently has a consensus rating of “Hold” and a consensus target price of $30.00.

ImageneBio Trading Up 2.9%

The firm’s fifty day moving average price is $5.76 and its 200-day moving average price is $6.02. The company has a market cap of $61.34 million, a P/E ratio of -0.99 and a beta of 0.73.

ImageneBio (NASDAQ:IMA) last released its earnings results on Thursday, May 7th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.25). As a group, research analysts forecast that ImageneBio, Inc. will post -3.66 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ImageneBio

Several large investors have recently added to or reduced their stakes in IMA. Barclays PLC lifted its position in shares of ImageneBio by 170.8% in the 4th quarter. Barclays PLC now owns 10,797 shares of the company’s stock worth $74,000 after acquiring an additional 6,810 shares during the period. Goldman Sachs Group Inc. acquired a new position in shares of ImageneBio in the fourth quarter valued at $76,000. Millennium Management LLC acquired a new position in shares of ImageneBio in the fourth quarter valued at $79,000. T3 Companies LLC bought a new position in ImageneBio in the fourth quarter worth $91,000. Finally, Jane Street Group LLC bought a new position in ImageneBio in the fourth quarter worth $103,000. Institutional investors and hedge funds own 75.00% of the company’s stock.

About ImageneBio

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025. ImageneBio, Inc is headquartered in San Diego, California.